CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Mineralys Therapeutics, Inc.

MLYS
$2.48BMid Cap

Next catalyst

PDUFADec 22, 2026in 35 days

Lorundrostat

Hypertension, in combination with other antihypertensive drugs

Get an email about MLYS's next catalysts

Track Mineralys Therapeutics (MLYS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (regulatory event).See the timeline

Catalyst Timeline

2 upcoming, 1 past

Regulatory

Regulatory

Dec 1, 2026

A Mineralys insider realized a $557,000 options gain ahead of a December FDA decision date. The article reports insider trading activity without providing details on the drug, indication, or regulatory decision type.

Source
PDUFANext

FDA PDUFA Date lorundrostat

Dec 22, 2026Lorundrostat

For Hypertension, in combination with other antihypertensive drugs. NDA. Verified against the company announcement on 2026-10-16.

Source

Upcoming FDA decisions

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaRADNOR51 employees
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Mineralys Therapeutics, Inc.'s drug pipeline?β†’

CatalystAlert tracks 5 drug candidates in Mineralys Therapeutics, Inc.'s (MLYS) pipeline across Phase 3, Phase 2. Its lead program is Lorundrostat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Mineralys Therapeutics, Inc.'s next FDA catalyst?β†’

Mineralys Therapeutics, Inc.'s (MLYS) next tracked catalyst is a PDUFA date expected Dec 22, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track MLYS biotech catalysts?β†’

Add MLYS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mineralys Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply